Abstract: The present invention relates to a pharmaceutical composition for oral administration in which a fumagillol derivative is stabilized and exhibits remarkable antiangiogenesis activity in oral administration.

Abstract: The retortable multilayer container of the present invention includes a receptacle and lid having at least a barrier layer includes an LCP film and inner food contact layer comprising at least one thermoplastic material. The receptacle has a base portion and a sidewall portion extending from the base portion defining a storage compartment. The storage compartment has a filling volume from about 0.03 to about 20 liters. The receptacle may be in the form of a tray, cup, bowl, tub or bucket. The tray may be designed as a simple tray or a multi-compartment tray. The receptacle may further have a lip portion extending from the sidewall portion providing an area for the lid to rest.

Abstract: The present invention provides a method for inducing reendothelialization of the lining of an injured blood vessel comprising contacting the injured portion of the vessel with nucleic acid encoding an endothelial cell mitogen such as vascular endothelial growth factor (VEGF) operably linked to a promoter to result in expression of the mitogen when delivered to the cells at the site of vascular injury. The resulting reendothelialization of the injured blood vessel inhibits smooth muscle cell proliferation and consequently reduces restenosis. The methods of the present invention may be used to treat any blood vessel injury that results in denuding of the endothelial lining of the vessel wall, including, for example, those injuries resulting from balloon angioplasty and deployment of endovascular stents.

Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).

Abstract: A thermoinsulative protective garment comprising a first, outer, waterproof but vapor permeable, garment part for covering at least a part of the body of a wearer (preferably the whole body) and a second, inner, thermoinsulative garment part constituting a lining for the first garment part and sealingly bonded to the first garment part at least at the aperture(s) of the garment, so as to provide a layer of air between the garment parts, the second garment part including a thermoinsulative fabric sheet comprising a substantially impermeable closed-cell elastomeric (e.g.

Abstract: The present invention relates to a process for producing L-tryptophan in a single-stage reaction, comprising carrying out an L-tryptophan producing reaction with glycine, formaldehyde and indole as raw materials in an aqueous solution in the presence of microbial cells having serine transhydroxymethylase or a treated products thereof and microbial cells having tryptophan synthase or tryptophanase, or a treated products thereof; and collecting produced L-tryptophan from the reaction solution.

Abstract: Disclosed are (1) a DNA containing a cDNA segment coding for human endothelin-2 (SEQ ID NO:1), (2) a precursor of human endothelin-2 (SEQ ID NO:2), (3) a transformant carrying a DNA containing a cDNA segment coding for human endothelin-2, and (4) a method for preparing mature human endothelin-2 which comprises culturing the transformant described in (3), accumulating a protein in a culture medium, and collecting the same, whereby human endothelin-2 and the precursors thereof can be produced in large amounts.

Abstract: According to this invention, antibodies which are useful and novel in that they have binding specificity to .beta.-amyloids or derivatives thereof, namely recognize the N-terminal, the C-terminal or central portions of the .beta.-amyloids, respectively, were obtained. By combining these antibodies, determination methods by which the .beta.-amyloids could be determined sensitively and specifically are provided. These determination methods are useful for diagnosis of diseases to which the .beta.-amyloids or their derivatives are related (for example, Alzheimer's disease), and the antibodies of this invention are useful for the development of preventive-therapeutic compositions for Alzheimer's disease.

Abstract: A black-type recording liquid, even when used for ink-jet recording instruments or for recording with ordinary writing instruments on plain paper, is capable of forming a recorded image with high printing quality: high density, excellent color tone, and excellent water and light resistance, and is highly stable when stored for a long time.

Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).

Abstract: The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof.

Abstract: Disclosed are (1) a DNA containing a synthetic gene for expression of human parathyroid hormone represented by the following DNA sequence:TCTGTG TCCGAGATTC AGTTAATGCA TAACCTTGGC AAACATTTGA ACTCCATGGA GCGTGTAGAA TGGCTGCGTA AGAAGTTGCA GGATGTGCAC AATTTTGTTG CCTTAGGTGC CCCATTGGCT CCTCGTGATG CTGGTTCCCA AAGACCACGT AAAAAGGAAG ACAATGTCTT AGTTGAGAGC CATGAAAAAT CCCTAGGCGA GGCAGACAAG GCCGATGTGA ATGTATTAAC TAAAGCTAAA TCCCAG(2) a method for producing the DNA described in (1), which comprises enzymatically ligating a plurality of oligodeoxynucleotides to one another to form the DNA and inserting the DNA into a vector if necessary, (3) a transformant transformed by the DNA described in (1), and (4) a method for producing human parathyroid hormone which comprises cultivating the transformant described in (3), accumulating human parathyroid hormone in a culture medium, and collecting the same, whereby hPTH can be allowed to express in large amounts in a system using E. coli as a host.

Abstract: An ophthalmic preparation which comprises a fumagillol derivative represented by the general formula(I): ##STR1## wherein R.sup.1 is hydrogen; R.sup.2 is a halogen, N(O).sub.m R.sup.5 R.sup.6, N.sup.+ R.sup.5 R.sup.6 R.sup.7 .multidot.X.sup.-, S(O).sub.n R.sup.5 or S.sup.+ R.sup.5 R.sup.6 .multidot.X.sup.-, wherein R.sup.5, R.sup.6 and R.sup.7 represent independently a substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted heterocyclic group; X.sup.- represents a counter anion; m represents 0 or 1; n represents an integer from 0 to 2; or R.sup.5 and R.sup.6 together with the adjacent nitrogen or sulfur atom may form a substituted or unsubstituted nitrogen- or sulfur-containing heterocyclic group which may form a condensed ring; or R.sup.1 and R.sup.2 are combined to represent a chemical bond; R.sup.3 is a substituted or unsubstituted 2-methyl-l-propenyl group or a substituted or unsubstituted isobutyl group; A is oxygen or NR.sup.8, wherein R.sup.

Abstract: Disclosed are CHO cells which are capable of continued production of human LH-RH receptor proteins, or cell membrane fractions thereof; recombinant human LH-RH receptor proteins or partial peptides thereof; methods for screening compounds which have affinity for an LH-RH receptor by contacting the compound with the CHO cells or the cell membrane fractions thereof, or the recombinant human LH-RH receptor proteins or the partial peptides thereof; kits for screening them; the compounds which have affinity for the LH-RH receptor obtained by methods for the screening or kits for the screening; and pharmaceutical compositions containing the compound, thereby being able to early provide prophylactic or therapeutic compositions, for example, for prostate cancer, uterine cancer, breast cancer, a pituitary tumor, endometriosis, hysteromyoma or precocious puberty. They are also useful as a pregnancy controlling composition such as contraceptive or a menstrual cycle controlling composition.